Formulary
Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide: Indications, Dosing, Side Effects and Interactions
Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide: Indications, Dosing, Side Effects and Interactions
Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**HIV-1 infection (specialist use only)**
- **Adult** (By Mouth): 1 tablet once daily.
**HIV-1 infection (specialist use only) for elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide**
- **Child 6-11 years (body-weight 25 kg and above)** (By mouth): 1 tablet once daily.
- **Child 12-17 years (body-weight 35 kg and above)** (By mouth): 1 tablet once daily.
Side effects
For elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide Common or very common Abnormal dreams; diarrhoea; dizziness; fatigue; flatulence; gastrointestinal discomfort; headache; nausea; skin reactions; vomiting Uncommon Anaemia; depression; suicidal behaviours Frequency not known Nephrotoxicity; osteonecrosis; weight increased
Pregnancy
Important safety information For elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide MHRA/CHM advice: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (April 2019) Pharmacokinetic data show mean exposure of elvitegravir boosted with cobicistat (available in combination in Genvoya and Stribild ) to be lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child. For further information, see Pregnancy .
Hepatic impairment
For elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide Manufacturer advises caution (increased risk of hepatic side-effects); avoid in severe impairment (no information available).
Renal impairment
For elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide Manufacturer advises avoid if creatinine clearance less than 30 mL/minute-limited information available. See Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

